Development trend analysis of ranolazine, based on bibliometrics.

ABSTRACT:

Background

Ranolazine is a highly effective inhibitor of the late sodium current and has been received approval from the FDA in 2006 for the treatment of chronic angina. To date, nearly 2000 papers have been published on it. It has demonstrated therapeutic potential in various fields, but uncertainties regarding its efficacy, safety risks, and limitations in expanding indications have hindered its clinical application. Therefore, we believe that the current period is the best time to conduct bibliometric analysis to overcome existing challenges and optimize interdisciplinary strategies.

Methods

We searched and downloaded the papers in the Science Citation Index Expanded database of the Web of Science Core Collection on September 1, 2025. Microsoft Excel was applied to organi

SUBMITTER: Zhang J 

PROVIDER: S-EPMC12622643 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature